person · Reporting owner

Strobeck Matthew

Disclosed activity across 5 companies

Tapewire entity: 42321
SEC CIK: 0001377832

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Accelerate Diagnostics, IncAXDX · Entity 78156	Director	January 23, 2024	January 25, 2024
BIODESIX INCBDSX · Entity 6053	Director	January 02, 2026	January 06, 2026
ELUTIA INC.ELUT · Entity 7342	10% owner in previous filing	March 23, 2023	February 20, 2024
QuidelOrtho CorpQDEL · Entity 4986	Director	May 29, 2026	June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date January 23, 2024 · Filed January 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Birchview Fund, LLC	120,682	Reported balance After 2024-01-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 120,682 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2029-01-23	IndirectBy Birchview Fund, LLC	100,000	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 100,000 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	202,556	Reported balance Holding disclosure · report date 2024-01-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 202,556
Common StockSEC Table I · non-derivative	IndirectAs UGMA Custodian for minor children	2,000	Reported balance Holding disclosure · report date 2024-01-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 2,000

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.

F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

BIODESIX INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	6,804	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 6,804 · Balance 6,804 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01	Direct	6,354	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

ELUTIA INC.

Report date March 23, 2023 · Filed February 20, 2024 · Amendment

Jointly reported with Birchview Capital, LP, Birchview Fund LLC

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,615,184	Reported balance After 2023-03-23 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-03-23 · Purchase · Acquired 100,000 · Balance 1,615,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,625,184	Reported balance After 2023-03-23 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2023-03-23 · Purchase · Acquired 10,000 · Balance 1,625,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,643,184	Reported balance After 2023-03-24 transaction · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · 2023-03-24 · Purchase · Acquired 18,000 · Balance 1,643,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,645,184	Reported balance After 2023-03-24 transaction · row 4 Amendment: may correct only part of an earlier disclosure. 1 source row Row 4 · 2023-03-24 · Purchase · Acquired 2,000 · Balance 1,645,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,655,184	Reported balance After 2023-03-27 transaction · row 5 Amendment: may correct only part of an earlier disclosure. 1 source row Row 5 · 2023-03-27 · Purchase · Acquired 10,000 · Balance 1,655,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.

Filing footnotes · ownership attribution and instrument terms

F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund.

F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.

F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").

F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.

QuidelOrtho Corp

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,604	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Grant · Acquired 6,829 · Balance 34,604 F1: Reflects release of restricted stock units that were previously reported on a Form 4.
Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Exercise / conversion · Disposed 6,829 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5: The restricted stock units vested on May 29, 2026.
Common StockSEC Table I · non-derivative	IndirectUGMA Account	16,630	Reported balance Holding disclosure · report date 2026-05-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 16,630 F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBirchview	38,145	Reported balance Holding disclosure · report date 2026-05-29 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 38,145 F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects release of restricted stock units that were previously reported on a Form 4.

F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

F5: The restricted stock units vested on May 29, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

QUIDEL CORP /DE/

Report date May 27, 2022 · Filed June 01, 2022

Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-27 transaction · row 1 1 source row Row 1 · 2022-05-27 · Disposition to issuer · Disposed 6,533 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Common StockSEC Table I · non-derivative	IndirectUGMA Account	Reported balance After 2022-05-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-05-27 · Disposition to issuer · Disposed 16,630 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBirchview	Reported balance After 2022-05-27 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-05-27 · Disposition to issuer · Disposed 38,145 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $53.27 · Expires 2028-04-04	Direct	Reported balance After 2022-05-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-27 · Disposition to issuer · Disposed 259 · Balance 0 F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5: Vested in full.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-27 · Disposition to issuer · Disposed 875 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-27 · Disposition to issuer · Disposed 262 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-05-27 · Disposition to issuer · Disposed 427 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-05-27 · Disposition to issuer · Disposed 85 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.

F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F5: Vested in full.

F6: Each restricted stock unit represents the right to receive one share of Quidel common stock.

F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 29, 2026 Filed Jun 2, 2026 20:11 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001377832-26-000005 · wk-form4_1780431068.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vested on May 29, 2026. F5 · derivative.expiration_date: The restricted stock units vested on May 29, 2026. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:11 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	6,829	$0.00	$0.00	Disclosure SEC source: 0001377832-26-000005 · wk-form4_1780431068.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,604 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
February 13, 2026 Filed Feb 13, 2026 21:20 UTC	QuidelOrtho Corp QDEL · Entity 4986	PurchaseCommon Stock	10,000	$23.96	$239,586.00	Disclosure SEC source: 0001377832-26-000003 · wk-form4_1771017605.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,775 F1 · price: The weighted average purchase price of these transactions was $23.9586 per share, with a range of $23.7600 to $23.9999 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:27 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	6,354	$0.00 Strike: $6.46	$0.00	Disclosure SEC source: 0000905148-26-000073 · form4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires 2036-01-01 F4 · derivative.exercise_date: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:27 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	6,804	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000073 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,804 Underlying: Common Stock · 6,804 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:13 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000122 · wk-form4_1748895176.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document
May 22, 2025 Filed May 27, 2025 20:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	4,929	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000099 · wk-form4_1748377717.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vested on May 22, 2025. F5 · derivative.expiration_date: The restricted stock units vested on May 22, 2025. Read SEC document
May 22, 2025 Filed May 27, 2025 20:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	4,929	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000099 · wk-form4_1748377717.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,775 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 20, 2025 Filed May 22, 2025 20:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	42,010	$0.00 Strike: $0.27	$0.00	Disclosure SEC source: 0000905148-25-001897 · form4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,010 Underlying: Common Stock · 42,010 shares Expires 2035-05-19 F4 · derivative.exercise_date: This option will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 20, 2025 Filed May 22, 2025 20:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	80,525	$0.00	$0.00	Disclosure SEC source: 0000905148-25-001897 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,525 Underlying: Common Stock · 80,525 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
November 05, 2024 Filed Nov 6, 2024 20:16 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	36,000	$1.40	$50,324.40	Disclosure SEC source: 0000905148-24-002950 · form4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 2,606,879 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.38 to $1.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 05, 2024 Filed Nov 6, 2024 20:16 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	4,000	$1.40	$5,591.60	Disclosure SEC source: 0000905148-24-002950 · form4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Capital Separately Managed Account Disclosed balance after: 89,673 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.38 to $1.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 24, 2024 Filed May 29, 2024 20:41 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	2,416	$0.00	$0.00	Disclosure SEC source: 0000950170-24-066008 · ownership.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vested on May 24, 2024. F5 · derivative.expiration_date: The restricted stock units vested on May 24, 2024. Read SEC document
May 24, 2024 Filed May 29, 2024 20:41 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	2,416	$0.00	$0.00	Disclosure SEC source: 0000950170-24-066008 · ownership.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,846 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 23, 2024 Filed May 23, 2024 23:15 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionSeries A Non-Voting Convertible Preferred Stock · Derivative	7,392	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001615 · form4.xml · derivative · entry 12 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 0 Underlying: Common Stock · 295,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.exercise_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.expiration_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 23, 2024 Filed May 23, 2024 23:15 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionSeries A Non-Voting Convertible Preferred Stock · Derivative	1,304	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001615 · form4.xml · derivative · entry 11 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Capital Separately Managed Account Disclosed balance after: 0 Underlying: Common Stock · 52,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.exercise_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F1 · derivative.expiration_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 23, 2024 Filed May 23, 2024 23:15 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	295,680	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-001615 · form4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 2,570,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 23, 2024 Filed May 23, 2024 23:15 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	52,160	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-24-001615 · form4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Capital Separately Managed Account Disclosed balance after: 85,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 22, 2024 Filed May 23, 2024 22:29 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	4,929	$0.00	$0.00	Disclosure SEC source: 0000950170-24-064147 · ownership.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,929 Underlying: Common Stock · 4,929 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 22, 2025. F2 · derivative.expiration_date: The restricted stock units vest on May 22, 2025. Read SEC document
May 21, 2024 Filed May 23, 2024 23:15 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	37,050	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0000905148-24-001615 · form4.xml · derivative · entry 10 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,050 Underlying: Common Stock · 37,050 shares Expires 2034-05-20 F8 · derivative.exercise_date: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
May 21, 2024 Filed May 23, 2024 23:15 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	53,726	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001615 · form4.xml · derivative · entry 9 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,726 Underlying: Common Stock · 53,726 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock. F6 · derivative.exercise_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F6 · derivative.expiration_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F7 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
April 05, 2024 Filed Apr 9, 2024 23:36 UTC	BIODESIX INC BDSX · Entity 6053	GrantSeries A Non-Voting Convertible Preferred Stock · Derivative	7,392	$46.00	$340,032.00	Disclosure SEC source: 0000905148-24-001143 · form4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 7,392 Underlying: Common Stock · 295,680 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F2 · ownership.direct: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
April 05, 2024 Filed Apr 9, 2024 23:36 UTC	BIODESIX INC BDSX · Entity 6053	GrantSeries A Non-Voting Convertible Preferred Stock · Derivative	1,304	$46.00	$59,984.00	Disclosure SEC source: 0000905148-24-001143 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Capital Separately Managed Account Disclosed balance after: 1,304 Underlying: Common Stock · 52,160 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date. F2 · ownership.direct: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:12 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock Warrants (right to buy) · Derivative	100,000	Not disclosed Strike: $1.65	Not disclosed	Disclosure SEC source: 0001104659-24-006678 · tm244005-7_4seq1.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund, LLC Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-23 F1 · price: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:12 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-006678 · tm244005-7_4seq1.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund, LLC Disclosed balance after: 120,682 F1 · price: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:19 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	105,389	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000044 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,036 Underlying: Common Stock · 105,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	13,580	$1.62	$21,999.60	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 7 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Capital Separately Managed Account Disclosed balance after: 33,513 F2 · ownership.direct: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	140,123	$1.62	$226,999.26	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 2,275,199 F2 · ownership.direct: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	6,790	$1.62	$10,999.80	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By UTMA Account Disclosed balance after: 119,003 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	6,790	$1.62	$10,999.80	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By UTMA Account Disclosed balance after: 119,003 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	6,790	$1.62	$10,999.80	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By UTMA Account Disclosed balance after: 119,003 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	6,790	$1.62	$10,999.80	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By UTMA Account Disclosed balance after: 119,003 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:33 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	127,777	$1.62	$206,998.74	Disclosure SEC source: 0000905148-23-000628 · form4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,542,928 Read SEC document
June 28, 2023 Filed Jun 29, 2023 17:55 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	236,842	$0.00	$0.00	Disclosure SEC source: 0001628280-23-023934 · wk-form4_1688075727.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,842 Underlying: Common Stock · 236,842 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: On June 28, 2023, the reporting person was granted RSUs which vest in equal amounts each year for 5 years, with the first installment vesting on June 28, 2024. F3 · derivative.expiration_date: Not applicable. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:31 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	2,248	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035426 · doc4.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vested on June 6, 2023. F5 · derivative.expiration_date: The restricted stock units vested on June 6, 2023. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:31 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	2,248	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035426 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,430 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 29, 2023 Filed Jun 1, 2023 18:25 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	78,947	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020563 · wk-form4_1685658315.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,947 Underlying: Common Stock · 78,947 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: On May 29, 2023, the reporting person was granted RSUs. All of the RSUs shall vest on the first-year anniversary of the Date of Grant (the "Vesting Date"), unless Grantee leaves in good standing before 12 months, in which case they will vest pro-rata based on months served. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 24, 2023 Filed May 26, 2023 00:22 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	2,416	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032335 · doc4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 2,416 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. Read SEC document
May 23, 2023 Filed May 25, 2023 22:22 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	34,647	$0.00	$0.00	Disclosure SEC source: 0001140361-23-026719 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,647 Underlying: Common Stock · 34,647 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F4 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. F4 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
May 18, 2023 Filed May 22, 2023 20:08 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Premium) · Derivative	85	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031413 · doc4.xml · derivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F5 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 18, 2023 Filed May 22, 2023 20:08 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Converted) · Derivative	427	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031413 · doc4.xml · derivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F5 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 18, 2023 Filed May 22, 2023 20:08 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	85	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031413 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,182 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 18, 2023 Filed May 22, 2023 20:08 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	427	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031413 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,097 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 14, 2023 Filed May 16, 2023 22:21 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Premium) · Derivative	262	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029932 · doc4.xml · derivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F5 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 14, 2023 Filed May 16, 2023 22:21 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Converted) · Derivative	875	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029932 · doc4.xml · derivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F5 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 14, 2023 Filed May 16, 2023 22:21 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	262	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029932 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,670 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 14, 2023 Filed May 16, 2023 22:21 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	875	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029932 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,408 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
March 27, 2023 Filed Mar 27, 2023 20:17 UTC	ELUTIA INC. AZYO · Entity 7342	PurchaseClass A Common Stock	10,000	$1.59	$15,870.00	Disclosure SEC source: 0001104659-23-037129 · tm2310663-1_4seq1.xml · nonDerivative · entry 5 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,655,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above. Read SEC document
March 27, 2023 Filed Feb 20, 2024 17:27 UTC Amendment	ELUTIA INC. ELUT · Entity 7342	PurchaseClass A Common Stock	10,000	$1.59	$15,870.00	Disclosure SEC source: 0001104659-24-025392 · tm246490-2_4aseq1.xml · nonDerivative · entry 5 Birchview Capital, LP · CIK 0001618205 · 10% owner in previous filing Birchview Fund LLC · CIK 0001603544 · 10% owner in previous filing Strobeck Matthew · CIK 0001377832 · 10% owner in previous filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,655,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above. Read SEC document
March 24, 2023 Filed Mar 27, 2023 20:17 UTC	ELUTIA INC. AZYO · Entity 7342	PurchaseClass A Common Stock	2,000	$1.35	$2,707.80	Disclosure SEC source: 0001104659-23-037129 · tm2310663-1_4seq1.xml · nonDerivative · entry 4 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,645,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA"). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.